EIT Pharma
PrivateLast Round
Series A
Aug 31, 2026
Total Funding Raised
$35M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
EIT Pharma operates in Healthcare & Life Sciences and is based in Kirkland, Washington. Its latest recorded funding round was a Series A round in August 2026.
EIT Pharma is a biotechnology company that develops therapies for infectious diseases, including treatments for chronic hepatitis D and acute respiratory infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EIT Pharma Comparables
Compare EIT Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shanghai Hepu Pharmaceutical Co., Ltd. | 79% | |
| Huahui Health Ltd. | 78% | |
| Mirum Pharmaceuticals | 78% |
For institutional investors. Book with your work email.
EIT Pharma Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
EIT Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kayne Anderson Capital Advisors | Series A |
| Propel Bio Partners | Series A |
| Good Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 31, 2026
$35M round led by Propel Bio Partners.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 27, 2026
EIT Pharma, Inc. appoints Dr. Joseph Toerner as Chief Medical Officer, effective immediately, to provide medical and clinical leadership across its infectious-disease development programs in Washington on Oct 27th '26.
- attends_eventOct 20, 2026
EIT Pharma, Inc. highlights three presentations on its lonafarnib development program at the 5th Edition of the Delta Cure International Meeting in Italy on Oct 20th '26.
- receives_financingAug 31, 2026
EIT Pharma, Inc. closes an oversubscribed $35M Series A led by Propel Bio Partners, with participation from Good Ventures and Arrowtown, in Washington on Aug 31st '26 to support FDA review and manufacturing and commercial readiness for lonafarnib, subject to regulatory approval, as well as its infectious disease pipeline.
- hiresAug 25, 2026
EIT Pharma, Inc. hires former Athira Pharma CEO Leen Kawas as its CEO in Washington on Aug 25th '26 as it develops treatments for chronic hepatitis D.
For institutional investors. Book with your work email.
EIT Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EIT Pharma's valuation, stock price, and market status.
Is EIT Pharma a public or private company?
EIT Pharma is a private company.
What is the current stock price of EIT Pharma?
EIT Pharma is a private company, so its shares have no public market price. Caplight tracks EIT Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EIT Pharma worth (valuation)?
Valuation information for EIT Pharma is not publicly available.
Can I buy EIT Pharma stock?
EIT Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EIT Pharma's last funding round?
EIT Pharma's most recent funding round was Series A on August 31, 2026.
Who are the main investors in EIT Pharma?
Key investors in EIT Pharma include Propel Bio Partners.
Will EIT Pharma IPO soon?
No public IPO plans have been announced for EIT Pharma.
How can I track EIT Pharma secondary market activity?
Caplight tracks bids, offers, and trades in EIT Pharma's shares on secondary markets.